Division of Genomic Epidemiology and Clinical Trials, Clinical Trials Research Center, Nihon University School of Medicine, 30-1 Oyaguchi-Kamimachi, Itabashi-ku, Tokyo, 173-8610, Japan.
Division of Companion Diagnostics, Department of Pathology and Microbiology, Nihon University School of Medicine, 30-1 Oyaguchi-Kamimachi, Itabashi-ku, Tokyo, 173-8610, Japan.
Drugs R D. 2017 Sep;17(3):403-412. doi: 10.1007/s40268-017-0191-y.
We conducted a retrospective cohort study to evaluate and compare the longitudinal effect of monotherapy with L-, L/T-, L/N-, and L/N/T-type calcium channel blockers (CCBs) on estimated glomerular filtration rate (eGFR), and to investigate the association of treatment duration with eGFR in diabetic patients with hypertension.
Using a clinical database, we identified new users of five CCBs, i.e. amlodipine (L-type, n = 693), nifedipine (L-type, n = 189), azelnidipine (L/T-type, n = 91), benidipine (L/N/T-type, n = 183), and cilnidipine (L/N-type, n = 61). We used a multivariable regression model to evaluate and compare the effects of these drugs on eGFR and serum creatinine, up to 12 months after initiation of study drug administration.
There was no significant association between treatment duration and both eGFR and serum creatinine level with all CCB types. In addition, there was no significant difference in mean change in eGFR among the five CCBs, with any treatment duration.
Our findings suggest that monotherapy with an L-, L/T-, L/N/T-, or L/N-type CCB may have little influence on renal function parameters and may be safely used in hypertensive patients with diabetes.
我们进行了一项回顾性队列研究,评估和比较了 L、L/T、L/N 和 L/N/T 型钙通道阻滞剂(CCB)单药治疗对估算肾小球滤过率(eGFR)的纵向影响,并探讨了治疗持续时间与糖尿病合并高血压患者 eGFR 的关系。
我们使用临床数据库,确定了五种 CCB 的新使用者,即氨氯地平(L 型,n=693)、硝苯地平(L 型,n=189)、阿折地平(L/T 型,n=91)、贝尼地平(L/N/T 型,n=183)和西尼地平(L/N 型,n=61)。我们使用多变量回归模型评估和比较了这些药物对 eGFR 和血清肌酐的影响,直到研究药物给药后 12 个月。
在所有 CCB 类型中,治疗持续时间与 eGFR 和血清肌酐水平均无显著相关性。此外,在任何治疗持续时间内,五种 CCB 之间 eGFR 的平均变化均无显著差异。
我们的研究结果表明,L、L/T、L/N/T 或 L/N 型 CCB 单药治疗可能对肾功能参数影响不大,可安全用于糖尿病合并高血压患者。